Equity Brief · Healthcare2026-05-20
ABT·Healthcare

Abbott Laboratories

I · Analyse IA

En bref

Abbott makes and sells healthcare products worldwide across four main areas: generic pharmaceuticals for chronic conditions, laboratory diagnostic systems and rapid tests, infant formula and nutritional products for children and adults, and medical devices including heart valves, glucose monitors, and pacemakers [Yahoo Finance]. The company serves hospitals, clinics, pharmacies, and consumers in both developed and emerging markets.

Abbott Laboratories is a diversified healthcare giant operating across four major segments: established pharmaceuticals, diagnostic products, nutritional products, and medical devices [Yahoo Finance]. The company generates $44.3B in annual revenue with strong margins and minimal debt, earning a perfect 10.0/10 financial health score [Yahoo Finance]. Recent strategic moves include a $21B acquisition of cancer diagnostics firm Exact Sciences and a pivot toward volume-driven nutrition sales, though the nutrition division contracted 6% in early 2026 [Yahoo Finance].

Abbott maintains exceptionally strong financial health with minimal debt, robust cash generation, and consistent profitability.

En bref AI analysisConfiance 8/10

Score Sentinellis

10/10

Financially healthy

Capitalisation boursière

$154.7B

Chiffre d'affaires (12 mois)

$44.3B

II · Actualités récentes

Ce qui a fait bouger le cours

6 stories · ranked by relevance

  • macro2026-05-20

    Abbott's Biosimilar Push to Help Sustain EPD Growth Momentum

    Yahoo Finance

  • macro2026-05-18

    ABT vs. ZBH: Which Surgical Equipment Stock Is the Better Bet Now?

    Yahoo Finance

  • macro2026-05-19

    Abbott Laboratories Insiders Added US$4.23m Of Stock To Their Holdings

    Yahoo Finance

  • macro2026-05-18

    Kernicterus Market Research and Forecast Report 2026-2036 Featuring Pfizer, F.Hoffmann La Roche,. Merck, AbbVie, AsteraZeneca, Abbott Laboratories, Sanofi, GlaxoSmithKline, Grifols

    Yahoo Finance

  • macro2026-05-18

    Hepatic Cirrhosis Market Research and Forecast Report 2026-2036, Profiles of Abbott, Astellas Pharma, Gilead Sciences, Novartis, Takeda Pharma, Grifols Therapeutics, and Cellaion

    Yahoo Finance

  • macro2026-05-18

    Wearables in Pharma & Biotech Research and Forecasts Report 2026-2031, Company Profiles and Market Strategies of Abbott, Dexcom, and Masimo

    Yahoo Finance

Premium · gratuit avec tout compte

The nutrition division shrank 6% in early 2026 due to price increases that backfired by reducing customer purchases, loss of a major U.S. government contract for low-income family nutrition products, and persistently high raw material costs since the pandemic [Yahoo Finance]

1 sur 4 risques dans ce rapport

Risques

4

Opportunités

6

Signaux d'alerte

2

Direction

10

21 autres constats dans le rapport complet — gratuit avec tout compte.

Débloquer l'analyse complète de Abbott Laboratories

Créez un compte gratuit pour accéder au rapport complet généré par IA, avec les sources citées dans le texte.

  • 4 risques, 6 opportunités et 2 signaux d'alerte — chacun avec sa source
  • Plus de 100 indicateurs financiers avec graphiques et comparaisons
  • Résumés d'actualités complets avec liens vers les sources
  • Équipe dirigeante et rémunération
  • Export PDF pour la lecture hors ligne
Débloquer les 12 constats3 rapports gratuits · sans carte

III · Entreprises similaires

À lire également

Same sector · Healthcare or comparable health

L'ajouter à votre liste ?

Read three companies free. Sans carte.

Obtenir 3 rapports gratuits